Financial Performance - The company's operating revenue for 2024 reached ¥2,930,677,498.58, an increase of 8.85% compared to ¥2,692,511,461.24 in 2023[15]. - Net profit attributable to shareholders for 2024 was ¥512,377,174.16, representing a 39.13% increase from ¥368,260,790.68 in 2023[15]. - The cash flow from operating activities for 2024 was ¥746,364,584.85, up 73.10% from ¥431,185,028.10 in 2023[15]. - Basic earnings per share for 2024 were ¥1.05, a 36.36% increase from ¥0.77 in 2023[15]. - Total assets at the end of 2024 amounted to ¥3,373,131,232.71, reflecting a 17.48% increase from ¥2,871,199,809.89 at the end of 2023[15]. - The company achieved a consolidated revenue of CNY 293,067.75 million in 2024, representing an 8.85% increase year-over-year[77]. - The net profit attributable to shareholders reached CNY 51,237.72 million, a 39.13% increase compared to the previous year[77]. - The revenue from drug formulations was CNY 2,357,173,125.6, accounting for 80.43% of total revenue, with a growth of 5.40% year-on-year[91]. Dividend Distribution - The company plans to distribute a cash dividend of 3.10 CNY per 10 shares (including tax) based on a total of 495,896,815 shares[3]. - The cash dividend distribution accounts for 100% of the total distributable profit of RMB 512,377,174.16[188]. - The company has no plans for stock dividends or capital reserve transfers in the current profit distribution proposal[187]. Research and Development - The company is actively pursuing research and development in both pharmaceutical formulations and excipients, aiming to enhance its competitive edge in the market[30]. - The R&D pipeline includes 31 projects, with 14 active pharmaceutical ingredients and 17 excipients, focusing on cutting-edge fields such as oncology and diabetes[56]. - The company has maintained a stable R&D investment of over 10% of revenue for several years, with a research team of over 100 members and a laboratory area exceeding 2,000 square meters[56]. - The company is focusing on expanding its product offerings and enhancing its market presence through new drug registrations and certifications[46]. - The company is committed to continuous improvement in product quality and compliance with GMP standards throughout the production process[38]. Market Position and Strategy - The company anticipates continued stable growth in the pharmaceutical sector through 2025, driven by increasing health awareness and government investment in healthcare[27]. - The company has established a strong presence in over 60 countries, including the US, Japan, and Europe, due to its advanced manufacturing technology and quality assurance systems[29]. - The company is actively pursuing market expansion strategies, targeting new geographic regions to enhance its market presence[136]. - The company is considering strategic acquisitions to bolster its competitive position in the market[136]. - The company has a commitment to quality management, as evidenced by the role of the quality director in the supervisory board[168]. Governance and Compliance - The company has a comprehensive governance structure, including a board of directors and supervisory board[4]. - The company emphasizes the importance of risk awareness regarding forward-looking statements and future plans[3]. - The company adheres to strict governance practices in line with the Company Law and Securities Law, ensuring stable development and protection of investor rights[142]. - The company has established a performance evaluation and incentive mechanism for directors and senior management to ensure fairness and effectiveness in assessments[149]. - The company has implemented a "Quality and Return Dual Improvement" action plan, although details on its disclosure were not provided[140]. Investor Relations - The company has a dedicated investor relations team to handle inquiries and disclosures[12]. - The company held multiple investor meetings throughout 2024, with a total of 301 participants in the April 25 meeting alone[135]. - The company is focusing on expanding its investor relations activities, as evidenced by the diverse range of institutional investors participating in the meetings[135]. - The company is committed to providing detailed insights into its financial and operational conditions during investor interactions[135]. - The company has been proactive in addressing investor inquiries and concerns through various communication channels[135]. Product Development and Innovation - The company has developed high-end excipients, with 103 registered varieties, of which 58 are in A status, particularly excipients for biological vaccines reaching advanced international standards[30]. - The company is actively expanding its product pipeline, with several new drug formulations in the registration process, indicating a commitment to innovation[40]. - The company has registered multiple new excipient products, all of which are in the production application stage[42]. - The company has introduced new products such as Indobufen Tablets and Vildagliptin Tablets, which are included in the National Medical Insurance Drug List[46]. - The company is pursuing a strategy of continuous innovation, as evidenced by the diverse range of products in various stages of development[41]. Risk Management - The company emphasizes quality control through process innovation and compliance management, aiming to enhance product competitiveness[127]. - The company acknowledges the potential for R&D risks due to market demand fluctuations and insufficient funding for product development[130]. - The company recognizes the impact of talent retention on R&D project progress, emphasizing the need for a stable and skilled workforce[131]. - The company is subject to regulatory requirements for drug production licenses, which must be renewed timely to avoid operational disruptions[131]. - The company faces risks related to concentrated procurement policies that may impact sales of key products, such as Loxoprofen Sodium Gel and Pantoprazole Sodium Enteric-Coated Tablets[129]. Environmental and Social Responsibility - The company has received multiple awards for its commitment to safety and environmental protection, including national-level green factory recognition[74]. - The company has implemented wastewater treatment capabilities of 1,200 tons per day and air treatment of 38,000 cubic meters per hour[75]. - The pharmaceutical industry involves complex production processes with significant environmental impacts, and stricter future environmental regulations may increase operational costs[133]. Human Resources - The company has a total of 2,221 employees, with 971 in production, 442 in sales, and 492 in technical roles, reflecting a balanced workforce[183]. - The company emphasizes talent development through a three-tier training system, enhancing employee satisfaction and loyalty[185]. - The company has identified no significant risks during the supervisory activities of the supervisory board in the reporting period[182]. - The company has a dynamic compensation system based on performance, capability assessment, and job value, aiming to motivate employees and align their interests with the company's growth[184].

Financial Performance - The company's revenue for Q1 2025 was CNY 696,028,386.21, representing a 17.79% increase compared to CNY 590,896,382.47 in the same period last year[6] - Net profit attributable to shareholders was CNY 125,775,709.52, a slight increase of 0.08% from CNY 125,669,473.12 year-on-year[6] - Basic earnings per share decreased by 30.56% to CNY 0.25, compared to CNY 0.36 in the same period last year[6] - Total operating revenue for the current period reached ¥696,028,386.21, an increase of 17.76% compared to ¥590,896,382.47 in the previous period[22] - Net profit for the current period was ¥125,775,709.52, slightly up from ¥125,669,473.12, reflecting a marginal increase of 0.08%[23] - The total comprehensive income for the current period was ¥125,775,709.52, slightly higher than ¥125,669,473.12 in the previous period[24] Cash Flow - The net cash flow from operating activities decreased by 38.15% to CNY 147,303,852.15, down from CNY 238,171,199.76 in the previous year[6] - Cash flow from operating activities generated a net amount of ¥147,303,852.15, down 38.19% from ¥238,171,199.76 in the prior period[26] - Net cash flow from investment activities was -$44.91 million, a decrease from -$126.37 million year-over-year[27] - Total cash inflow from financing activities was $56.78 million, compared to $9.00 million in the previous period[27] - Cash and cash equivalents increased by $153.21 million, up from $108.85 million year-over-year[27] - Cash outflow for investment activities totaled $246.16 million, an increase from $126.42 million year-over-year[27] - Cash outflow for financing activities was $5.96 million, compared to $11.95 million in the previous period[27] - Cash inflow from investment activities amounted to $201.25 million, up from $46,000 in the previous period[27] - Cash paid for the acquisition of fixed assets and intangible assets was $66.16 million, down from $86.42 million year-over-year[27] - Cash received from investment income was $1.25 million, unchanged from the previous period[27] Assets and Liabilities - Total assets increased by 3.43% to CNY 3,488,955,041.56 from CNY 3,373,131,232.71 at the end of the previous year[6] - Current assets totaled CNY 1,676,547,724.08, up from CNY 1,601,774,702.04, indicating an increase of about 4.7%[19] - Cash and cash equivalents rose to CNY 588,329,341.07 from CNY 443,307,337.44, marking a significant increase of approximately 32.7%[17] - The company's accounts receivable decreased to CNY 332,261,404.58 from CNY 350,502,639.39, a decline of about 5.2%[17] - Inventory levels remained stable, with a slight decrease from CNY 367,704,817.24 to CNY 366,528,565.07, a change of approximately -0.3%[17] - Total liabilities decreased from CNY 391,863,535.79 to CNY 294,960,082.37, representing a reduction of about 24.7%[19] - Long-term borrowings increased by 43.61% to CNY 183,696,080.00, attributed to stock repurchase loans and project loans[10] - Long-term borrowings increased to CNY 183,696,080.00 from CNY 127,913,000.00, reflecting a growth of approximately 43.6%[19] - Total liabilities amounted to ¥839,592,801.00, a decrease of 0.96% from ¥846,401,371.85[20] - Total equity attributable to shareholders reached ¥2,649,362,240.56, an increase of 4.83% from ¥2,526,729,860.86[20] Research and Development - The company reported a 54.19% increase in R&D expenses, totaling CNY 63,106,394.07, compared to CNY 40,928,107.97 in the previous year[10] - Research and development expenses increased to ¥63,106,394.07, a rise of 54.36% compared to ¥40,928,107.97 in the previous period[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 43,861[12] - The company reported a total of 125,061,391 shares with restricted sales at the end of the period, up from 124,305,686 shares at the beginning[15] Other Information - The company experienced a significant increase of 3330.65% in special reserves, amounting to CNY 295,936.61, due to increased safety investment reserves[10] - The company reported a decrease in other income by 72.23%, totaling CNY 6,907,915.13, primarily due to a reduction in government subsidies received[10] - The company has not disclosed any new product developments or market expansion strategies during this reporting period[16]

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-018 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）于 2025 年 2 月 17 日召开 第四届董事会第九次会议，审议通过了《关于回购公司股份方案的议案》，同意 公司通过集中竞价交易方式以自有资金和股票回购专项贷款资金回购部分社会 公众股份，用于后期实施股权激励计划。本次回购的资金总额不低于人民币 10,000 万元且不超过人民币 15,000 万元，回购价格不超过人民币 24.98 元/股， 实施期限为自董事会审议通过回购股份方案之日起 12 个月内。具体内容详见公 司在巨潮资讯网披露的《回购股份报告书》（公告编号：2025-012）等相关公告。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等有关 规定，回购期间公司应当在每个月的前三个交易日内披露截 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-017 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于 2025 年第一季度可转换公司债券转股情况的公告 特别提示： 1、九典转02转股期限为2024年3月21日至2029年9月14日，最新转股价格为 15.33元/股。 2、2025年第一季度，共有383张九典转02完成转股，对应票面金额为38,300 元，转股数量为2,495股。 3、截至2025年第一季度末，九典转02剩余2,053,514张，对应票面金额为 205,351,400元。 根据《深圳证券交易所创业板股票上市规则》有关规定，湖南九典制药股份 有限公司（以下简称"公司"）现将2025年第一季度可转换公司债券（以下简称 "可转债"）转股及公司股份变动情况公告如下： 一、可转换公司债券基本情况 转股期限自 2024 年 3 月 21 日起至 2029 年 9 月 14 日止。 二、可转债转 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-016 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于股东减持股份的预披露公告 股东熊英保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有本公司股份 720,929 股（占本公司总股本比例 0.145%）的财务总监熊 英女士，计划在本公告披露之日起 15 个交易日后的 3 个月内以集中竞价方式减 持本公司股份不超过 180,232 股（占本公司总股本比例 0.036%）。 公司于近日收到熊英女士出具的《股份减持计划告知函》。现将相关情况公 告如下： 二、本次减持计划的主要内容 | 股东名称 | 减持原因 | 股份来源 | 减持数量及比例 | 减持方式 | 减持期间 | 减持价格 | | --- | --- | --- | --- | --- | --- | --- | | 熊英 | 个人资金 | 公司首次公开 发行前已发行 的股份 ...

Group 1: Company Overview and Market Position - The company, Hunan Jiudian Pharmaceutical Co., Ltd., focuses on the production of external anti-inflammatory and analgesic products, specifically Loxoprofen and Ketoprofen gel patches, which are considered complementary in the market [2][3]. - The external patch market in 2023 has a sales scale of approximately ¥20.364 billion, with hospitals accounting for 69.89% and retail for 30.11% [4]. Group 2: Cost Control and Operational Efficiency - The company implements various measures for cost reduction, including self-production of raw materials and key auxiliary materials to ensure product quality while controlling costs [3]. - Continued efforts will be made to expand outpatient markets and optimize marketing models to further reduce sales expenses [5]. Group 3: Strategic Planning and Growth Potential - The company’s 2025 strategic plan focuses on three key areas: expanding sales channels, enhancing R&D for new product development, and optimizing production processes for efficient operations [7]. - There is significant growth potential for Loxoprofen sodium gel patches in the outpatient market, driven by stable demand and increasing consumer preference for convenient medication [8].

九典制药：招商证券、鹏扬基金等多家机构于3月25 日调研我司 证券之星消息，2025年3月25日九典制药（300705）发布公告称招商证券、鹏扬基金、圆信永丰基金 于2025年3月25日调研我司。 具体内容如下： 问：公司如何看待竞品获批对公司的影响？ 答：对于竞品获批公司将积极应对。在成本端，凭借完整的产业链布局，公司能够自主生产原料药和 关键辅料，确保产品质量的同时有效控制成本。在销售端，公司已建立起全渠道覆盖体系，特别是院外市 场，已成为业绩增长的新引擎，公司计划继续加大投入，以期在市场中占据更大份额。在研发端，公司始 终保持对研发的高投入，不断推陈出新，拓宽产品线。同时，公司将持续打造"久悦"贴膏品牌，通过先发 优势、渠道优势及成本优势等，致力于在经皮给药领域深化影响力，进一步稳固行业领先地位。 问：洛索洛芬钠凝胶贴膏在广东联盟集采的接续情况是怎样的？ 问：公司氟比洛芬凝胶贴膏预计何时获批？ 答：公司预计氟比洛芬凝胶贴膏将于今年底获批。 答：截至目前，洛索洛芬钠凝胶贴膏在广东联盟集采的接续工作尚处于报量阶段，采购文件暂未正式 发布。未来公司将持续关注广东联盟及全国集采相关动态，积极参与投标及接续工作。 ...

Group 1: Company Strategy and Market Position - The company plans to actively respond to the impact of competitor product approvals by leveraging its complete industrial chain to control costs and ensure product quality [2] - A full-channel coverage system has been established, particularly in the outpatient market, which has become a new growth engine for performance [2] - Continuous high investment in R&D is maintained to innovate and expand the product line, with a focus on strengthening the "JiuYue" brand in the transdermal drug delivery sector [2] Group 2: Product Development and Market Expansion - The company is currently in the reporting phase for the procurement of the Loxoprofen Sodium Gel Patch in the Guangdong Alliance, with procurement documents not yet officially released [3] - Plans to enhance sales strategies for the Loxoprofen Sodium Gel Patch include increasing resource allocation to the outpatient market to boost market influence [4] - As of December 31, 2024, over 2,000 hospitals have been developed for the Ketoprofen Gel Patch, including more than 1,000 tier 2 and tier 3 hospitals [5] Group 3: Consumer Demographics and Product Approval - The primary consumer demographics for the Loxoprofen Sodium Gel Patch in retail pharmacies include patients with osteoarthritis, muscle pain, injuries, elderly individuals, laborers, and athletes [6] - The company anticipates that the Fluorobiprofen Gel Patch will be approved by the end of this year [7] Group 4: Share Buyback Progress - The company conducted its first share buyback on March 13, 2025, through centralized bidding, with details available in the recent announcement on the Giant Tide Information Network [8]

Market Overview - The transdermal patch industry is experiencing rapid growth due to factors such as an aging population facing chronic pain issues like arthritis and muscle pain, which increases market demand for patch products [2][3] - Public awareness of scientific medication and health management is rising, leading to a preference for convenient and safe external medications like transdermal patches [2][3] Company Advantages - The company benefits from a complete industrial chain, allowing for in-house production of active pharmaceutical ingredients and key excipients, ensuring product quality while controlling costs [3][8] - A comprehensive sales channel system has been established, particularly in the outpatient market, which is a new growth engine for performance [3] - Continuous high investment in R&D enables the company to innovate and expand its product line, enhancing its competitive edge [3][8] Product Strategy - The company is optimistic about the market prospects for its anti-inflammatory and analgesic patches, focusing on OTC channels and leveraging shared sales resources to boost sales [4] - The sales team consists of over 400 personnel, enhancing the company's market reach [5] Marketing and Promotion - Multi-channel collaboration strategies are employed for OTC promotion, integrating online and offline channels, including partnerships with pharmacies and e-commerce platforms [6][10] - The company emphasizes patient education and conducts health seminars to enhance consumer experience and trust [7] Future Directions - The company plans to focus on three key areas: expanding sales channels, particularly in outpatient markets, enhancing brand influence, and increasing R&D efforts for new product development [12][13] - Continuous optimization of production processes and cost control mechanisms will be prioritized to ensure efficient operations and good returns for shareholders [13] M&A Strategy - The company will consider various directions for mergers and acquisitions, focusing on targets that align with its strategic development, enhance market competitiveness, and enrich its product pipeline [11]

湖南九典制药股份有限公司 关于为全资子公司提供担保的进展公告 | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-015 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 以上担保金额在公司已履行审议程序的担保额度以内，无需履行其他审议程 序。本次担保生效后，公司为九典宏阳提供担保的剩余总额度为人民币 27,700 万元整。 三、被担保人情况 公司名称：湖南九典宏阳制药有限公司 统一社会信用代码：91430122344723202P 类型：有限责任公司（自然人投资或控股的法人独资） 住所：湖南望城经济开发区铜官循环经济工业基地内 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 湖南九典制药股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日、2024 年 5 月 15 日分别召开的第四届董事会第四次会议及 2023 年度股东大会审议通 过了《关于为全资子公司申请银行授信提供担保的议案》，同意公司为全资子公 司湖南九典宏阳制药有限公司（以下简称"九典宏 ...